Dysregulation of Nav1.6 has been associated with AD, and our laboratory previously demonstrated that reducing Nav1.6 expression alleviates AD‐related pathological features by downregulating β‐site APP‐cleaving enzyme 1 (BACE1) transcription.21 Here, BACE1 is linked to Alzheimer disease.